Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (19287)	3/15/2006 11:44:50 AM
From: nigel bates	Read Replies (1) of 52153

Very nasty. Any way of predicting the likely cause ? It's a mAB, so off target effects unlikely ? (CD28 agonist - Message 22261812 ) TeGenero has identified a functionally novel class of proprietary “superagonistic” monoclonal antibodies (SuperMAB®) directed against the important immuno- regulatory T cell antigen CD28. CD28 is the most efficient CD receptor that co-stimulates T cells in combination with the TCR. Activation of the CD28 signaling pathway requires simultaneous triggering of the TCR by antigen and of CD28 by its physiological membrane-bound ligands. In vitro, this process can be mimicked by using a combination of MABs with specificity for the TCR and CD28. TeGenero´s novel CD28-SuperMAB®, bypasses the requirement for TCR signaling and activates T cells regardless of their TCR specificity. CD28-SuperMAB® therefore represents the first universal T cell growth factor applicable for therapeutic purpose in the intact organism... Contamination ? Hit the front pages in the UK, so I wouldn't like to be recruiting for any other PI trials right now...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next